Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Autor: Oliveira, Mafalda *, *, Rugo, Hope S *, Howell, Sacha J, Dalenc, Florence, Cortes, Javier, Gomez, Henry L, Hu, Xichun, Toi, Masakazu, Jhaveri, Komal, Krivorotko, Petr, Loibl, Sibylle, Morales Murillo, Serafin, Okera, Meena, Nowecki, Zbigniew, Park, Yeon Hee, Sohn, Joo Hyuk, Tokunaga, Eriko, Yousef, Samih, Zhukova, Lyudmila, Fulford, Marta, Andrews, Haylee, Wadsworth, Ian, D'Cruz, Celina, Turner, Nicholas C
Zdroj: In The Lancet Oncology September 2024 25(9):1231-1244
Databáze: ScienceDirect